BASE:ROSE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Instituto Rosenbusch S.A. researches, develops, manufactures, and sells veterinary products in Argentina. More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Instituto Rosenbusch's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ROSE is more volatile than 90% of AR stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ROSE's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of AR stocks.


Market Performance


7 Day Return

-8.2%

ROSE

-0.9%

AR Pharmaceuticals

-3.4%

AR Market


1 Year Return

88.8%

ROSE

-2.3%

AR Pharmaceuticals

25.8%

AR Market

Return vs Industry: ROSE exceeded the AR Pharmaceuticals industry which returned -5.2% over the past year.

Return vs Market: ROSE exceeded the AR Market which returned 14.3% over the past year.


Shareholder returns

ROSEIndustryMarket
7 Day-8.2%-0.9%-3.4%
30 Day-13.7%-2.1%-1.5%
90 Day-13.7%6.2%-12.8%
1 Year88.8%88.8%0.4%-2.3%26.5%25.8%
3 Year22.9%22.9%11.6%3.1%32.9%24.5%
5 Year129.5%129.5%43.6%25.9%195.3%158.7%

Long-Term Price Volatility Vs. Market

How volatile is Instituto Rosenbusch's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Instituto Rosenbusch undervalued compared to its fair value and its price relative to the market?

3.42x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: ROSE (ARS10.1) is trading above our estimate of fair value (ARS0.55)

Significantly Below Fair Value: ROSE is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ROSE is unprofitable, so we can't compare its PE Ratio to the XX Pharmaceuticals industry average.

PE vs Market: ROSE is unprofitable, so we can't compare its PE Ratio to the AR market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ROSE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ROSE is overvalued based on its PB Ratio (3.4x) compared to the XS Pharmaceuticals industry average (3.3x).


Next Steps

Future Growth

How is Instituto Rosenbusch forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Instituto Rosenbusch has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Instituto Rosenbusch performed over the past 5 years?

-49.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ROSE is currently unprofitable.

Growing Profit Margin: ROSE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ROSE is unprofitable, and losses have increased over the past 5 years at a rate of 49.7% per year.

Accelerating Growth: Unable to compare ROSE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ROSE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.4%).


Return on Equity

High ROE: ROSE has a negative Return on Equity (2.13%), as it is currently unprofitable.


Next Steps

Financial Health

How is Instituto Rosenbusch's financial position?


Financial Position Analysis

Short Term Liabilities: ROSE's short term assets (ARS470.9M) exceed its short term liabilities (ARS440.4M).

Long Term Liabilities: ROSE's short term assets (ARS470.9M) exceed its long term liabilities (ARS19.6M).


Debt to Equity History and Analysis

Debt Level: ROSE's debt to equity ratio (104.3%) is considered high.

Reducing Debt: ROSE's debt to equity ratio has increased from 34.8% to 104.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable ROSE has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: ROSE is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 31.7% per year.


Next Steps

Dividend

What is Instituto Rosenbusch current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ROSE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ROSE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ROSE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ROSE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ROSE's dividend in 3 years as they are not forecast to pay a notable one for the AR market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Rodolfo Martín Balestrini

no data

Tenure

Dr. Rodolfo Martín Balestrini serves as the President of Instituto Rosenbusch S.A. Dr. Balestrini serves as Chairman of the Board of Directors at Instituto Rosenbusch S.A.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Instituto Rosenbusch S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Instituto Rosenbusch S.A.
  • Ticker: ROSE
  • Exchange: BASE
  • Founded: 1917
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AR$430.154m
  • Shares outstanding: 42.59m
  • Website: https://www.rosenbusch.com

Location

  • Instituto Rosenbusch S.A.
  • Hipólito Yrigoyen 1628 (C1089AAF)
  • Buenos Aires
  • 1136
  • Argentina

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ROSEBASE (Buenos Aires Stock Exchange)YesClass B Common StockARARSSep 1999

Biography

Instituto Rosenbusch S.A. researches, develops, manufactures, and sells veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory and nervous...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/02/25 22:03
End of Day Share Price2021/02/23 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.